{
    "startDate": "2021-08-01",
    "endDate": "2022-01-31",
    "year": "2022",
    "quarter": "Q2",
    "symbol": "RFL",
    "data": {
        "bs": [
            {
                "label": "Accrued expenses",
                "concept": "AccruedLiabilitiesCurrent",
                "unit": "usd",
                "value": 6622000
            },
            {
                "label": "Trade accounts receivable, net of allowance for doubtful accounts of $230 and $193 at January 31, 2022 and July 31, 2021, respectively",
                "concept": "ReceivablesNetCurrent",
                "unit": "usd",
                "value": 616000
            },
            {
                "label": "Restricted cash",
                "concept": "RestrictedCashCurrent",
                "unit": "usd",
                "value": 5000000
            },
            {
                "label": "Other assets",
                "concept": "OtherAssetsNoncurrent",
                "unit": "usd",
                "value": 1410000
            },
            {
                "label": "In-process research and development and patents",
                "concept": "rfl:InProcessResearchAndDevelopment",
                "unit": "usd",
                "value": 1575000
            },
            {
                "label": "Total equity attributable to Rafael Holdings, Inc.",
                "concept": "StockholdersEquity",
                "unit": "usd",
                "value": 102877000
            },
            {
                "label": "Investments \u2013 Other Pharmaceuticals",
                "concept": "rfl:InvestmentsOtherPharmaceuticals",
                "unit": "usd",
                "value": 477000
            },
            {
                "label": "Other liabilities",
                "concept": "OtherLiabilitiesNoncurrent",
                "unit": "usd",
                "value": 84000
            },
            {
                "label": "Property and equipment, net",
                "concept": "PropertyPlantAndEquipmentNet",
                "unit": "usd",
                "value": 42537000
            },
            {
                "label": "Due to related parties",
                "concept": "DueToRelatedPartiesCurrent",
                "unit": "usd",
                "value": 57000
            },
            {
                "label": "Class B common stock, $0.01 par value; 200,000,000 shares authorized, 19,051,500 issued and 19,029,012 outstanding as of January 31, 2022, and 16,947,066 issued and 16,936,864 outstanding as of July 31, 2021",
                "concept": "rfl:CommonStockValue1",
                "unit": "usd",
                "value": 190000
            },
            {
                "label": "Due from RP Finance LLC, net of allowance for losses on related party receivables of $9,375 and $0 at January 31, 2022 and July 31, 2021, respectively",
                "concept": "DeferredIncomeTaxAssetsNet",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "TOTAL ASSETS",
                "concept": "Assets",
                "unit": "usd",
                "value": 122568000
            },
            {
                "label": "Trade accounts payable",
                "concept": "AccountsPayableCurrent",
                "unit": "usd",
                "value": 1125000
            },
            {
                "label": "Total current assets",
                "concept": "AssetsCurrent",
                "unit": "usd",
                "value": 71544000
            },
            {
                "label": "Equity investment \u2013 RP Finance LLC",
                "concept": "rfl:EquityInvestmentRPFinance",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Investments \u2013 Hedge Funds",
                "concept": "rfl:InvestmentsHedgeFunds",
                "unit": "usd",
                "value": 5025000
            },
            {
                "label": "Due from Rafael Pharmaceuticals, net of allowance for losses on related party receivables of $720 and $0 at January 31, 2022 and July 31, 2021, respectively",
                "concept": "rfl:DueFromRafaelPharmaceuticals",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Additional paid-in capital",
                "concept": "AdditionalPaidInCapital",
                "unit": "usd",
                "value": 253896000
            },
            {
                "label": "Other current liabilities",
                "concept": "OtherLiabilitiesCurrent",
                "unit": "usd",
                "value": 246000
            },
            {
                "label": "TOTAL LIABILITIES",
                "concept": "Liabilities",
                "unit": "usd",
                "value": 22912000
            },
            {
                "label": "Investments \u2013 Rafael Pharmaceuticals",
                "concept": "LongTermInvestments",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "COMMITMENTS AND CONTINGENCIES",
                "concept": "CommitmentsAndContingencies",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Cash and cash equivalents",
                "concept": "CashEquivalentsAtCarryingValue",
                "unit": "usd",
                "value": 65025000
            },
            {
                "label": "Accumulated deficit",
                "concept": "RetainedEarningsAccumulatedDeficit",
                "unit": "usd",
                "value": -155144000
            },
            {
                "label": "TOTAL EQUITY",
                "concept": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": 99656000
            },
            {
                "label": "TOTAL EQUITY",
                "concept": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": 99656000
            },
            {
                "label": "TOTAL EQUITY",
                "concept": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": 99656000
            },
            {
                "label": "Noncontrolling interests",
                "concept": "MinorityInterest",
                "unit": "usd",
                "value": -3221000
            },
            {
                "label": "Total current liabilities",
                "concept": "LiabilitiesCurrent",
                "unit": "usd",
                "value": 22828000
            },
            {
                "label": "Class A common stock, $0.01 par value; 35,000,000 shares authorized, 787,163 shares issued and outstanding as of January 31, 2022 and July 31, 2021, respectively",
                "concept": "CommonStockValue",
                "unit": "usd",
                "value": 8000
            },
            {
                "label": "TOTAL LIABILITIES AND EQUITY",
                "concept": "LiabilitiesAndStockholdersEquity",
                "unit": "usd",
                "value": 122568000
            }
        ],
        "cf": [
            {
                "label": "",
                "concept": "IncomeLossFromEquityMethodInvestments",
                "unit": "usd",
                "value": -575000
            },
            {
                "label": "",
                "concept": "IncomeLossFromEquityMethodInvestments",
                "unit": "usd",
                "value": -575000
            },
            {
                "label": "Purchases of property and equipment",
                "concept": "PaymentsToAcquirePropertyPlantAndEquipment",
                "unit": "usd",
                "value": 62000
            },
            {
                "label": "Trade accounts receivable",
                "concept": "IncreaseDecreaseInAccountsReceivable",
                "unit": "usd",
                "value": 418000
            },
            {
                "label": "Other liabilities",
                "concept": "rfl:IncreaseDecreaseInOtherLiabilities",
                "unit": "usd",
                "value": 36000
            },
            {
                "label": "Net increase (decrease) in cash and cash equivalents, and restricted cash",
                "concept": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
                "unit": "usd",
                "value": 57171000
            },
            {
                "label": "Amortization of debt discount",
                "concept": "AmortizationOfDebtDiscountPremium",
                "unit": "usd",
                "value": 250000
            },
            {
                "label": "Other assets",
                "concept": "IncreaseDecreaseInOtherOperatingAssets",
                "unit": "usd",
                "value": -107000
            },
            {
                "label": "Provision for losses on related party receivables",
                "concept": "rfl:ProvisionForLossesOnRelatedPartyReceivables",
                "unit": "usd",
                "value": 10095000
            },
            {
                "label": "Provision for losses on related party receivables",
                "concept": "rfl:ProvisionForLossesOnRelatedPartyReceivables",
                "unit": "usd",
                "value": 10095000
            },
            {
                "label": "Impairment of cost method investment - Rafael Pharmaceuticals",
                "concept": "rfl:ImpairmentOfCostMethodInvestmentRafaelPharmaceuticals",
                "unit": "usd",
                "value": 79141000
            },
            {
                "label": "Impairment of cost method investment - Rafael Pharmaceuticals",
                "concept": "rfl:ImpairmentOfCostMethodInvestmentRafaelPharmaceuticals",
                "unit": "usd",
                "value": 79141000
            },
            {
                "label": "Provision for loss on receivable pursuant to line of credit",
                "concept": "rfl:ProvisionForLossOnReceivablePursuantToLineOfCredit",
                "unit": "usd",
                "value": 25000000
            },
            {
                "label": "Provision for loss on receivable pursuant to line of credit",
                "concept": "rfl:ProvisionForLossOnReceivablePursuantToLineOfCredit",
                "unit": "usd",
                "value": 25000000
            },
            {
                "label": "Due from Rafael Pharmaceuticals",
                "concept": "rfl:IncreaseDecreaseInDueFromRafaelPharmaceuticals",
                "unit": "usd",
                "value": 120000
            },
            {
                "label": "Contribution from noncontrolling interest of consolidated entity",
                "concept": "rfl:ContributionFromNoncontrollingInterestOfConsolidatedEntity",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Restricted cash",
                "concept": "rfl:RestrictedCash1",
                "unit": "usd",
                "value": 5000000
            },
            {
                "label": "Payment to Rafael Pharmaceuticals pursuant to Line of Credit",
                "concept": "rfl:PaymentToRafaelPharmaceuticalsPursuantToLineOfCredit",
                "unit": "usd",
                "value": 25000000
            },
            {
                "label": "Proceeds from sale of building",
                "concept": "ProceedsFromSaleOfPropertyPlantAndEquipment",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Investment in Rafael Pharmaceuticals",
                "concept": "PaymentsToAcquireInvestments",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Effect of exchange rate changes on cash and cash equivalents, and restricted cash",
                "concept": "EffectOfExchangeRateOnCashAndCashEquivalents",
                "unit": "usd",
                "value": 51000
            },
            {
                "label": "Accounts payable and accrued expenses",
                "concept": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
                "unit": "usd",
                "value": 5360000
            },
            {
                "label": "Prepaid expenses and other current assets",
                "concept": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
                "unit": "usd",
                "value": -172000
            },
            {
                "label": "Purchase of Investment in Altira",
                "concept": "PaymentsToAcquireShortTermInvestments",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Payment to fund RP Finance Line of Credit",
                "concept": "rfl:PaymentToFundRPFinanceLineOfCredit",
                "unit": "usd",
                "value": 1875000
            },
            {
                "label": "Proceeds from exercise of options",
                "concept": "ProceedsFromStockOptionsExercised",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Payment of transaction costs incurred in connection with sale of common stock",
                "concept": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
                "unit": "usd",
                "value": -6228000
            },
            {
                "label": "Deferred income taxes",
                "concept": "DeferredIncomeTaxesAndTaxCredits",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Stock-based compensation",
                "concept": "ShareBasedCompensation",
                "unit": "usd",
                "value": -3095000
            },
            {
                "label": "Stock-based compensation",
                "concept": "ShareBasedCompensation",
                "unit": "usd",
                "value": -3095000
            },
            {
                "label": "Acquisition of additional ownership interest in LipoMedix",
                "concept": "rfl:AcquisitionOfAdditionalOwnershipInterestInLipoMedix",
                "unit": "usd",
                "value": 8000
            },
            {
                "label": "Total cash and cash equivalents and restricted cash shown in statement of cash flows",
                "concept": "rfl:TotalCashCashEquivalentsAndRestrictedCashShownInStatementOfCashFlows",
                "unit": "usd",
                "value": 70025000
            },
            {
                "label": "Net cash used in operating activities",
                "concept": "NetCashProvidedByUsedInOperatingActivities",
                "unit": "usd",
                "value": -13811000
            },
            {
                "label": "Impairment of investments - Other Pharmaceuticals",
                "concept": "ImpairmentOfInvestments",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Impairment of investments - Other Pharmaceuticals",
                "concept": "ImpairmentOfInvestments",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Cash and cash equivalents",
                "concept": "rfl:CashAndCashEquivalents",
                "unit": "usd",
                "value": 65025000
            },
            {
                "label": "Depreciation and amortization",
                "concept": "DepreciationDepletionAndAmortization",
                "unit": "usd",
                "value": 763000
            },
            {
                "label": "",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -131976000
            },
            {
                "label": "",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -131976000
            },
            {
                "label": "",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -131976000
            },
            {
                "label": "Gain on sale of building",
                "concept": "GainLossOnSaleOfProperties",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Provision for doubtful accounts",
                "concept": "ProvisionForDoubtfulAccounts",
                "unit": "usd",
                "value": 37000
            },
            {
                "label": "Proceeds from issuance of common stock",
                "concept": "ProceedsFromIssuanceOfCommonStock",
                "unit": "usd",
                "value": 104167000
            },
            {
                "label": "Net cash used in investing activities",
                "concept": "NetCashProvidedByUsedInInvestingActivities",
                "unit": "usd",
                "value": -26937000
            },
            {
                "label": "Other current liabilities",
                "concept": "IncreaseDecreaseInOtherCurrentLiabilities",
                "unit": "usd",
                "value": 98000
            },
            {
                "label": "Impairment - Altira",
                "concept": "rfl:ImpairmentAltira",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Due to related parties",
                "concept": "IncreaseDecreaseInDueToRelatedParties",
                "unit": "usd",
                "value": -79000
            },
            {
                "label": "Net cash provided by financing activities",
                "concept": "NetCashProvidedByUsedInFinancingActivities",
                "unit": "usd",
                "value": 97868000
            },
            {
                "label": "Net unrealized (loss) gain on investments - Hedge Funds",
                "concept": "rfl:GainLossOnInvestmentsHedgeFund",
                "unit": "usd",
                "value": -243000
            },
            {
                "label": "Payments for taxes related to shares withheld for employee taxes",
                "concept": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
                "unit": "usd",
                "value": 71000
            },
            {
                "label": "Proceeds related to distribution from Hedge Funds",
                "concept": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
                "unit": "usd",
                "value": "N/A"
            }
        ],
        "ic": [
            {
                "label": "Equity in earnings (loss) of RP Finance",
                "concept": "IncomeLossFromEquityMethodInvestments",
                "unit": "usd",
                "value": -575000
            },
            {
                "label": "Equity in earnings (loss) of RP Finance",
                "concept": "IncomeLossFromEquityMethodInvestments",
                "unit": "usd",
                "value": -575000
            },
            {
                "label": "Foreign currency translation adjustment",
                "concept": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
                "unit": "usd",
                "value": -155000
            },
            {
                "label": "Total revenue",
                "concept": "Revenues",
                "unit": "usd",
                "value": 2136000
            },
            {
                "label": "Total revenue",
                "concept": "Revenues",
                "unit": "usd",
                "value": 2136000
            },
            {
                "label": "",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -131976000
            },
            {
                "label": "",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -131976000
            },
            {
                "label": "",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -131976000
            },
            {
                "label": "Research and development",
                "concept": "ResearchAndDevelopmentExpense",
                "unit": "usd",
                "value": 5488000
            },
            {
                "label": "Provision for losses on related party receivables",
                "concept": "rfl:ProvisionForLossesOnRelatedPartyReceivables",
                "unit": "usd",
                "value": 10095000
            },
            {
                "label": "Provision for losses on related party receivables",
                "concept": "rfl:ProvisionForLossesOnRelatedPartyReceivables",
                "unit": "usd",
                "value": 10095000
            },
            {
                "label": "",
                "concept": "rfl:ImpairmentOfCostMethodInvestmentRafaelPharmaceuticals",
                "unit": "usd",
                "value": 79141000
            },
            {
                "label": "",
                "concept": "rfl:ImpairmentOfCostMethodInvestmentRafaelPharmaceuticals",
                "unit": "usd",
                "value": 79141000
            },
            {
                "label": "Provision for loss on receivable pursuant to line of credit",
                "concept": "rfl:ProvisionForLossOnReceivablePursuantToLineOfCredit",
                "unit": "usd",
                "value": 25000000
            },
            {
                "label": "Provision for loss on receivable pursuant to line of credit",
                "concept": "rfl:ProvisionForLossOnReceivablePursuantToLineOfCredit",
                "unit": "usd",
                "value": 25000000
            },
            {
                "label": "Net loss attributable to Rafael Holdings, Inc.",
                "concept": "NetIncomeLossAvailableToCommonStockholdersBasic",
                "unit": "usd",
                "value": -114345000
            },
            {
                "label": "Other \u2013 Related Party",
                "concept": "rfl:RevenuesOtherRelatedParty",
                "unit": "usd",
                "value": 120000
            },
            {
                "label": "Rental \u2013 Related Party",
                "concept": "RevenueFromRelatedParties",
                "unit": "usd",
                "value": 1225000
            },
            {
                "label": "Net loss attributable to noncontrolling interests",
                "concept": "NetIncomeLossAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": -17631000
            },
            {
                "label": "Basic and diluted (in Dollars per share)",
                "concept": "EarningsPerShareBasicAndDiluted",
                "unit": "usd/shares",
                "value": -5.91
            },
            {
                "label": "Unrealized (loss) gain on investments \u2013 Hedge Funds",
                "concept": "rfl:UnrealizedGainOnInvestmentsHedgeFund",
                "unit": "usd",
                "value": 243000
            },
            {
                "label": "Depreciation and amortization",
                "concept": "DepreciationAndAmortization",
                "unit": "usd",
                "value": 763000
            },
            {
                "label": "Parking",
                "concept": "rfl:ParkingRevenues",
                "unit": "usd",
                "value": 363000
            },
            {
                "label": "Provision for income taxes",
                "concept": "IncomeTaxExpenseBenefit",
                "unit": "usd",
                "value": 4000
            },
            {
                "label": "Selling, general and administrative",
                "concept": "SellingGeneralAndAdministrativeExpense",
                "unit": "usd",
                "value": 11996000
            },
            {
                "label": "Basic and diluted (in Shares)",
                "concept": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
                "unit": "shares",
                "value": 19332630
            },
            {
                "label": "",
                "concept": "ImpairmentOfInvestments",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "",
                "concept": "ImpairmentOfInvestments",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Impairment \u2013 Altira",
                "concept": "RestructuringSettlementAndImpairmentProvisions",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Gain on sale of building",
                "concept": "MarketableSecuritiesGainLoss",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Comprehensive loss attributable to noncontrolling interests",
                "concept": "rfl:ComprehensiveLossAttributableToNoncontrollingInterests",
                "unit": "usd",
                "value": -17681000
            },
            {
                "label": "Interest expense, net",
                "concept": "ForeignCurrencyTransactionGainLossBeforeTax",
                "unit": "usd",
                "value": -807000
            },
            {
                "label": "Total comprehensive loss attributable to Rafael Holdings, Inc.",
                "concept": "ComprehensiveIncomeNetOfTax",
                "unit": "usd",
                "value": -114140000
            },
            {
                "label": "Rental \u2013 Third Party",
                "concept": "OperatingLeasesIncomeStatementLeaseRevenue",
                "unit": "usd",
                "value": 428000
            }
        ]
    }
}